巴瑞替尼单药或联合甲氨蝶呤对比甲氨蝶呤单药治疗早期类风湿关节炎的疼痛控制
本文为RA-BEGIN研究的事后分析,评估早期类风湿关节炎患者接受巴瑞替尼4 mg单药、巴瑞替尼4 mg联合甲氨蝶呤或甲氨蝶呤单药治疗52周期间疼痛改善的速度、幅度和维持情况。结果显示巴瑞替尼单药或联合甲氨蝶呤较甲氨蝶呤单药提供更大且更迅速的疼痛缓解,并增加有限至无疼痛的周数及SF-36 PCS的临床有意义改善。
要点
- 巴瑞替尼单药或联合甲氨蝶呤较甲氨蝶呤单药疼痛缓解更显著且更迅速。
- 巴瑞替尼单药或联合甲氨蝶呤增加9-10周有限至无疼痛时间。
- 巴瑞替尼单药或联合甲氨蝶呤在SF-36 PCS改善≥5分方面增加5-7周。
核心结论
- 巴瑞替尼单药或联合甲氨蝶呤治疗早期类风湿关节炎患者,较甲氨蝶呤单药在1年内报告显著更大且更迅速的疼痛缓解、更多有限至无疼痛周数及躯体健康的临床有意义改善。
研究设计与样本
- 随机、双盲、3期研究RA-BEGIN(NCT01711359)的事后分析,比较巴瑞替尼4 mg(N=159)、巴瑞替尼4 mg+甲氨蝶呤(N=215)和甲氨蝶呤(N=210)在无或有限既往改善病情抗风湿药治疗的类风湿关节炎患者中的效果。
- 疼痛采用0-100 mm视觉模拟量表(VAS)评估,评估52周内疼痛改善≥30%、≥50%、≥70%的患者比例、疼痛VAS≤20 mm和≤10 mm的患者比例及达到疼痛改善阈值的时间,同时评估患者总体评估(PtGA)和36项简短健康调查躯体成分评分(SF-36 PCS)。
主要发现
- 巴瑞替尼单药组和巴瑞替尼联合甲氨蝶呤组较甲氨蝶呤单药组提供更大疼痛缓解:最小二乘均值(LSM)较基线变化分别为-40 mm和-43 mm vs -31 mm。
- 巴瑞替尼单药组和联合组达到≥70%疼痛改善的中位时间分别为12周和8周,甲氨蝶呤单药组为20周。
- 巴瑞替尼单药或联合组较甲氨蝶呤单药组在1年内增加9-10周有限至无疼痛时间,PtGA达到可实现健康的增益相似,SF-36 PCS变化≥5分增加5-7周。
关键数值与推荐
- 疼痛改善阈值包括较基线改善≥30%、≥50%、≥70%,以及疼痛VAS≤20 mm和≤10 mm。
- 巴瑞替尼单药组LSM较基线变化-40 mm,巴瑞替尼联合甲氨蝶呤组-43 mm,甲氨蝶呤单药组-31 mm。
- 达到≥70%疼痛改善的中位时间:巴瑞替尼单药组12周,联合组8周,甲氨蝶呤单药组20周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This post hoc analysis assessed speed, magnitude and maintenance of pain improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib and methotrexate (MTX), or MTX over 1 year. Cumulative pain and quality of life benefits were also assessed. METHODS: Randomised, double-blind, phase 3 study RA-BEGIN (NCT01711359) compared baricitinib 4 mg (N=159), baricitinib 4 mg +MTX (N=215) and MTX (N=210) in patients with RA who had no or limited prior disease-modifying antirheumatic drug treatment. Pain was assessed on a 0-100 mm Visual Analogue Scale (VAS). Proportion of patients with ≥30%, ≥50% and ≥70% pain improvement from baseline; ≤20 mm and ≤10 mm on the pain VAS; and time to achieve pain improvement thresholds were assessed over 52 weeks, as were Patient Global Assessment (PtGA) and 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS) outcomes. RESULTS: Baricitinib monotherapy or combination with MTX provides greater (least square mean changes (LSM) from baseline -40 mm and -43 mm, respectively) and more rapid (median 12 and 8 weeks to ≥70% improvement, respectively) pain relief than MTX alone (LSM -31 mm, median 20 weeks to ≥70% improvement) over 52 weeks. Baricitinib, alone or combination, provides 9-10 additional weeks of limited to no pain, similar gain in achievable wellness measured through PtGA, and 5-7 additional weeks with change in SF-36 PCS ≥5 vs MTX over 1 year. CONCLUSIONS: Patients treated with baricitinib reported significantly greater and more rapid pain relief, more weeks with limited to no pain, and clinically meaningful improvements in physical health than patients treated with MTX alone over 1 year.
引用
- Taylor PC, Alten R, Álvaro Gracia JM, et al. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 2022. PMID: 35264432. doi:10.1136/rmdopen-2021-001994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。